ArunA Bio are the experts in the design and scaling of neural-derived exosomes, developing a new class of cell-free biologics and cell-mediated neural specific drug delivery systems to treat CNS and neurodegenerative disorders.
ArunA Bio has demonstrated the unique ability of exosomes to enhance the nervous system’s self-repair mechanisms through multi- modal mechanisms, leading to both structural and functional benefits in multiple preclinical models. And, ArunA’s neural-specific exosomes have unique qualities for delivering payloads to neural cells.
Company website: ArunA Bio
Back to companies
ArunA Bio has demonstrated the unique ability of exosomes to enhance the nervous system’s self-repair mechanisms through multi- modal mechanisms, leading to both structural and functional benefits in multiple preclinical models. And, ArunA’s neural-specific exosomes have unique qualities for delivering payloads to neural cells.
Company website: ArunA Bio
Back to companies
Location: United States, Georgia, Athens
Total raised: $18.3M
Investors 4
| Date | Name | Website |
| - | Georgia Re... | gra.org |
| - | GRA Ventur... | graventure... |
| - | Irrus Inve... | irrusinves... |
| - | Eshelman V... | eshelmanve... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 29.08.2019 | - | $13M | - |
| 27.09.2018 | - | $5.3M | - |
Mentions in press and media 7
| Date | Title | Description |
| 25.06.2021 | Roth Capital Partners to Host a Virtual Healthcare Private Company Forum on June 28, 2021 | NEWPORT BEACH, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Roth Capital Partners (“Roth”), www.roth.com, is set to virtually present the Roth Virtual Healthcare Private Company Forum on June 28th, 2021. This event will con... |
| 14.04.2021 | Aruna Bio Closes $10.8 Million Common Stock Financing | ATHENS, Ga. and RESEARCH TRIANGLE PARK, N.C., April 14, 2021 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in the development of neural exosomes for the treatment of neurodegenerative diseases, today announced the closing of a common stock ... |
| 29.07.2019 | Athens Biotech Firm Treating ALS, Strokes Raises $13M | ArunA Bio, a biotech company based in Athens, has raised $13 million from Eshelman Ventures, members of the company’s board of directors and management, and other investors. ArunA Bio will use the funding to support the development of its n... |
| 25.07.2019 | ArunA Bio Nabs $13M Common Stock Financing | ATHENS, GA, ArunA Bio today announced the completion of a $13 million common stock financing. >> Click here for more funding data on ArunA Bio >> To export ArunA Bio funding data to PDF and Excel, click here ArunA Bio, a ... |
| 24.07.2019 | ArunA Bio Raises $13 Million | ATHENS, Ga.--(BUSINESS WIRE)--ArunA Bio, Inc., a leader in the development of neural exosomes for the treatment of neurodegenerative diseases, today announced the completion of a $13 million common stock financing. Proceeds from the financi... |
| 24.07.2019 | ArunA Bio Raises $13M in Common Stock Financing | ArunA Bio, Inc., an Athens, Ga.-based leader in the development of neural exosomes for the treatment of neurodegenerative diseases, completed a $13m common stock financing. The financing included both existing and new private investors alon... |
| 27.09.2018 | ArunA Bio Raises $5.3M in Funding | ArunA Bio, an Athens, GA-based neural exosome therapeutic platform, secured $5.3m in funding. Backers included existing angel investors. The company intends to use the funds to further the development of its neural exosome therapeutic platf... |